MX2016006256A - Tratamiento de glaucoma usando laquinimod. - Google Patents
Tratamiento de glaucoma usando laquinimod.Info
- Publication number
- MX2016006256A MX2016006256A MX2016006256A MX2016006256A MX2016006256A MX 2016006256 A MX2016006256 A MX 2016006256A MX 2016006256 A MX2016006256 A MX 2016006256A MX 2016006256 A MX2016006256 A MX 2016006256A MX 2016006256 A MX2016006256 A MX 2016006256A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- glaucoma
- damage
- iop
- loss
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D1/00—Containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material, by deep-drawing operations performed on sheet material
- B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
- B65D1/0207—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents characterised by material, e.g. composition, physical features
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona un método para tratar un sujeto que padece de glaucoma, que padece de pérdida o daño de células ganglionares retínales (RGC), o presión intraocular elevada (IOP), o para reducir la pérdida o daño de RGC, o reducir la IOP en un sujeto, que comprende administrar al sujeto una cantidad de laquinimod efectiva para tratar al sujeto, para reducir la pérdida o daño de RGC, o para reducir la IOP en el sujeto. También se proporciona una composición farmacéutica, un paquete y un paquete terapéutico para tratar a un sujeto que padece de glaucoma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361904962P | 2013-11-15 | 2013-11-15 | |
PCT/US2014/065497 WO2015073697A1 (en) | 2013-11-15 | 2014-11-13 | Treatment of glaucoma using laquinimod |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016006256A true MX2016006256A (es) | 2016-09-07 |
Family
ID=53058023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006256A MX2016006256A (es) | 2013-11-15 | 2014-11-13 | Tratamiento de glaucoma usando laquinimod. |
Country Status (12)
Country | Link |
---|---|
US (6) | US20150141458A1 (es) |
EP (1) | EP3068395A4 (es) |
JP (1) | JP2016537364A (es) |
KR (1) | KR20160100302A (es) |
CN (1) | CN105960238A (es) |
AU (1) | AU2014348620A1 (es) |
CA (1) | CA2930113A1 (es) |
EA (1) | EA201690903A1 (es) |
HK (1) | HK1225971A1 (es) |
IL (1) | IL245373A0 (es) |
MX (1) | MX2016006256A (es) |
WO (1) | WO2015073697A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019182814A (ja) * | 2018-04-17 | 2019-10-24 | 国立大学法人九州大学 | 生体リズム調整剤及び生体リズム調整用医薬組成物 |
IL305997A (en) | 2021-04-01 | 2023-11-01 | Active Biotech Ab | Laquinimod formulation for ophthalmic use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2754712B1 (fr) * | 1996-10-17 | 1999-09-03 | Merck Sharp Dohme Chibret Lab | Compositions ophtalmiques |
WO2007005176A1 (en) * | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Pyrrolidinones for the treatment of glaucoma and ocular hypertension |
US8354428B2 (en) * | 2008-07-01 | 2013-01-15 | Actavis Group Ptc Ehf | Solid state forms of laquinimod and its sodium salt |
KR20120045032A (ko) * | 2009-07-30 | 2012-05-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 크론병의 치료 |
JP5859438B2 (ja) * | 2009-08-10 | 2016-02-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドを用いたbdnf関連疾患の治療 |
CN105944081A (zh) * | 2011-07-28 | 2016-09-21 | 泰华制药工业有限公司 | 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症 |
TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
-
2014
- 2014-11-13 AU AU2014348620A patent/AU2014348620A1/en not_active Abandoned
- 2014-11-13 CN CN201480062699.2A patent/CN105960238A/zh active Pending
- 2014-11-13 US US14/540,768 patent/US20150141458A1/en not_active Abandoned
- 2014-11-13 JP JP2016530937A patent/JP2016537364A/ja not_active Withdrawn
- 2014-11-13 CA CA2930113A patent/CA2930113A1/en not_active Abandoned
- 2014-11-13 EA EA201690903A patent/EA201690903A1/ru unknown
- 2014-11-13 KR KR1020167015972A patent/KR20160100302A/ko not_active Application Discontinuation
- 2014-11-13 MX MX2016006256A patent/MX2016006256A/es unknown
- 2014-11-13 EP EP14862075.0A patent/EP3068395A4/en not_active Withdrawn
- 2014-11-13 WO PCT/US2014/065497 patent/WO2015073697A1/en active Application Filing
-
2016
- 2016-05-02 IL IL245373A patent/IL245373A0/en unknown
- 2016-10-11 US US15/290,461 patent/US20170027927A1/en not_active Abandoned
- 2016-12-16 HK HK16114335A patent/HK1225971A1/zh unknown
-
2017
- 2017-01-24 US US15/414,406 patent/US20170128436A1/en not_active Abandoned
- 2017-06-01 US US15/611,578 patent/US20170266179A1/en not_active Abandoned
- 2017-09-11 US US15/701,168 patent/US20170368054A1/en not_active Abandoned
-
2018
- 2018-01-19 US US15/875,833 patent/US20180140593A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20170128436A1 (en) | 2017-05-11 |
AU2014348620A1 (en) | 2016-06-16 |
WO2015073697A1 (en) | 2015-05-21 |
HK1225971A1 (zh) | 2017-09-22 |
EP3068395A1 (en) | 2016-09-21 |
EP3068395A4 (en) | 2017-07-12 |
KR20160100302A (ko) | 2016-08-23 |
US20170027927A1 (en) | 2017-02-02 |
US20180140593A1 (en) | 2018-05-24 |
CN105960238A (zh) | 2016-09-21 |
US20150141458A1 (en) | 2015-05-21 |
JP2016537364A (ja) | 2016-12-01 |
CA2930113A1 (en) | 2015-05-21 |
EA201690903A1 (ru) | 2016-10-31 |
US20170266179A1 (en) | 2017-09-21 |
IL245373A0 (en) | 2016-06-30 |
US20170368054A1 (en) | 2017-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ704247A (en) | Compositions and treatment for eye diseases and disorders | |
MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
EA201390364A1 (ru) | Средство для лечения синдрома сухого глаза, характеризующееся комбинированием агониста рецептора pyи гиалуроновой кислоты или ее соли, способ лечения синдрома сухого глаза и применение агониста рецептора pyи гиалуроновой кислоты или ее соли | |
MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
WO2012080497A3 (en) | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases | |
EP4324454A3 (en) | Cross-linking agents and associated methods | |
MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MX2014005209A (es) | Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas. | |
MX2020011190A (es) | Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension. | |
WO2018102687A3 (en) | Combination therapy for treating cancer | |
PH12017500392A1 (en) | Medical treatments based on anamorelin | |
MX355853B (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
BR112015022044A2 (pt) | um método de proporcionar neutroproteção ocular | |
MX2016006256A (es) | Tratamiento de glaucoma usando laquinimod. | |
MX2019011925A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
MX2021014120A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
WO2012135814A3 (en) | Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy | |
EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
RU2013125864A (ru) | Способ лечения прогрессирующей миопии высокой степени | |
UA75277U (ru) | Способ лечения дистрофических заболеваний сетчатки и хориоидеи | |
NZ617069A (en) | Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury | |
WO2012135465A3 (en) | Treatment of glaucoma |